TIDMOPTI

RNS Number : 4610I

OptiBiotix Health PLC

02 April 2020

Opti B i otix Health plc

( "Opti Bi o t ix" or the "Company")

SlimBiome(R) contract manufacturing agreement with Fipros A/S

OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness d e vel o ping co m p o u n ds to tack le o besit y, high

choleste r ol, diabetes and skincare, a nn o unces it has entered into a contract manufacturing agreement with Fipros A/S ("Fipros") in Denmark.

Fipros ( www.fipros.dk ) is a Danish contract manufacturer founded in 1992 with operations in Sweden and Denmark. The terms of the agreement grant Fipros the rights to utilise OptiBiotix's IP to manufacture SlimBiome(R) under licence.

This is another strategic step by OptiBiotix to derisk its supply chain in case of a hard Brexit as the agreement creates a source of supply located within the European Union to support the commercial launch of SlimBiome(R) in Poland (RNS: 6 December 2019) and Germany (RNS: 19 December 2019).

Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division , c o mmented: "We are very pleased to work with Fipros to manufacture SlimBiome (R) within the European Union. The agreement is key as it helps us lower the cost of trade, support our existing and future European distributors and build contingency in the supply chain which is a key requirement from large commercial partners who do not want to be single-sourced. In addition, Fipros has a Certification and Accreditation Administration of the People's Republic of China (CNCA) registration thus enabling us to fast track future possible exports to China."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

For further information, please contact:

 
 OptiBiotix Health plc                                  www.optibiotix.com 
 Stephen O'Hara, Chief Executive                      Contact via Walbrook 
                                                                     below 
 
 Cairn Financial Advisers LLP (NOMAD)                   Tel: 020 7213 0880 
 Liam Murray / Jo Turner / Ludovico Lazzaretti 
 
 finnCap (Broker)                                       Tel: 020 7220 0500 
 Geoff Nash / Kate Bannatyne (Corporate Finance) 
 Camille Gochez (Corporate Broking) 
 
 goetzpartners securities Limited                       Tel: 0203 859 7725 
 Ulrich Kinzel 
 
 Walbrook PR Ltd                                        Mob: 07876 741 001 
 Anna Dunphy

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

AGRIBMITMTJMBLM

(END) Dow Jones Newswires

April 02, 2020 02:00 ET (06:00 GMT)

Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Optibiotix Health Charts.
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Optibiotix Health Charts.